Filing Flows › Aclaris Therapeutics (ACRS) › Recalls, complaints & regulation
Aclaris Therapeutics (ACRS): clinical trials
Aclaris Therapeutics (ACRS) beyond its filings: 1 active clinical trial.
Aclaris Therapeutics' latest quarter
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Aclaris Therapeutics have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.